We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.92B
AUM Growth
-$82.3M
Cap. Flow
-$215M
Cap. Flow %
-11.22%
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
2
ABT icon
Abbott
ABT
+$10.5M
3
OTLK icon
Outlook Therapeutics
OTLK
+$7.71M
4
BPTH
Bio-Path Holdings Inc
BPTH
+$7.56M
5
SHPG
Shire pic
SHPG
+$5.34M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$22.6M
2
BIIB icon
Biogen
BIIB
+$7.14M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$3.88M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.22M
5
ESRX
Express Scripts Holding Company
ESRX
+$2.84M

Sector Composition

Rank Sector Weight
1 Healthcare 12.85%
2 Industrials 0.12%
3 Consumer Staples 0.07%
4 Consumer Discretionary 0.06%
5 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPXX
176
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$800K 0.04%
26,500
+1,500
+6% +$30.4K
CYTXW
177
DELISTED
Cytori Therapeutics Inc Warrant
CYTXW
$793K 0.04%
+1,004,065
New +$674K
RCKT icon
178
Rocket Pharmaceuticals
RCKT
$343M
$792K 0.04%
26,614
-2,500
-9% -$87.9K
DERM
179
DELISTED
Dermira, Inc.
DERM
$781K 0.04%
26,693
-95,907
-78% -$2.65M
ACHN
180
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$780K 0.04%
1,000
-5
-0.5% -$43
HCA icon
181
PUT
HCA Healthcare
HCA
$92.8B
$770K 0.04%
+100
New +$7.89K
GNMX
182
DELISTED
Aevi Genomic Medicine Inc
GNMX
$770K 0.04%
+138,777
New +$729K
HZNP
183
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$763K 0.04%
463
+73
+19% +$1.18K
INSM icon
184
PUT
Insmed
INSM
$22.6B
$760K 0.04%
771
– –
CELG
185
PUT
DELISTED
Celgene Corp
CELG
$759K 0.04%
+77
New +$7.96K
ARLZ
186
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$754K 0.04%
228,364
-8,000
-3% -$30.2K
AST
187
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$741K 0.04%
+308,909
New +$1.12M
PGNX
188
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$738K 0.04%
174,900
-170,297
-49% -$822K
EYPT icon
189
EyePoint Inc
EYPT
$1B
$730K 0.04%
25,780
-3,579
-12% -$110K
PPBT
190
Purple Biotech
PPBT
$1.28M
$725K 0.04%
+116
New +$1.16M
CAPR icon
191
Capricor Therapeutics
CAPR
$380M
$719K 0.04%
18,208
-2,000
-10% -$70.6K
TPST icon
192
Tempest Therapeutics
TPST
$13.9M
$704K 0.04%
+46
New +$1.05M
GBT
193
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$698K 0.04%
421
-5,206
-93% -$105K
FOLD
194
DELISTED
Amicus Therapeutics
FOLD
$687K 0.04%
125,912
+66,588
+112% +$466K
ABEO icon
195
Abeona Therapeutics
ABEO
$343M
$637K 0.03%
10,800
-2,564
-19% -$175K
PARN
196
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$635K 0.03%
+389,400
New +$716K
SSKN
197
DELISTED
Strata Skin Sciences
SSKN
$623K 0.03%
20,410
+8,948
+78% +$360K
TMBR
198
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$622K 0.03%
64
+12
+23% +$135K
NUROW
199
DELISTED
NeuroMetrix, Inc. Warrants
NUROW
$612K 0.03%
38,252
-879
-2% -$20.5K
MCRB icon
200
Seres Therapeutics
MCRB
$46.5M
$598K 0.03%
1,030
-2,434
-70% -$1.43M
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $215M in Q2 2016, closing 99 positions and reducing 80 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Abbott worth $10.4M.

  • Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
  • Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
  • Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
  • Sabby Management opened 94 new positions and closed 99 in Q2 2016.
  • Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.